Key Events This Week
22 Jun: Upgrade to Buy rating by MarketsMOJO
23 Jun: Stock price nears 52-week high at ₹6,784.95
25 Jun: Sharp 14.1% surge in open interest amid price decline
26 Jun: Week closes at ₹6,710.85 (-0.45%)
22 June 2026: Upgrade to Buy Rating Sparks Optimism
On 22 June, MarketsMOJO upgraded Divis Laboratories Ltd from 'Hold' to 'Buy', citing strong technical and financial performance. This upgrade was driven by a marked improvement in weekly technical indicators such as MACD and Bollinger Bands, which turned decisively bullish. The stock opened the week at ₹6,741.15 and closed at ₹6,784.95, gaining 0.65% on the day and nearing its 52-week high of ₹7,077.70. This positive price action aligned with the upgrade, signalling renewed investor confidence.
Financially, the company reported record quarterly net sales of ₹2,831 crore and a PBDIT of ₹934 crore, marking its seventh consecutive quarter of positive results. The return on equity stood at a healthy 16.32%, and the company remained net-debt free, enhancing its financial stability. Institutional investors held a significant 39.51% stake, underscoring strong market trust. Despite a premium valuation with a price-to-book ratio of 10.7 and a PEG ratio of 3.5, the upgrade reflected balanced optimism based on quality fundamentals and technical momentum.
Strong fundamentals, solid momentum, fair price – This Large Cap from the NBFC sector checks every box for our Top 1%. This should definitely be on your radar!
- - Complete fundamentals package
- - Technical momentum confirmed
- - Reasonable valuation entry
23 June 2026: Price Nears 52-Week High Amid Mixed Market Sentiment
On 23 June, Divis Laboratories closed at ₹6,743.15, down 0.62% from the previous day’s close despite the broader Sensex falling 1.05%. The stock’s volume surged to 8,999 shares, reflecting active trading. The slight price decline amid a broader market sell-off suggested some profit-booking or short-term consolidation after the upgrade announcement. Nevertheless, the stock remained close to its recent highs, supported by strong technical indicators and positive fundamentals.
24 June 2026: Modest Recovery with Reduced Delivery Volumes
The stock edged up 0.12% to close at ₹6,751.05 on 24 June, while the Sensex gained 0.53%. However, delivery volumes declined by 23.76% to 1.42 lakh shares compared to the five-day average, indicating reduced conviction among long-term holders or profit-booking activity. This contrasted with the positive price movement and suggested a cautious stance among investors, possibly awaiting further clarity on sector or company developments.
25 June 2026: Sharp Surge in Open Interest Amid Price Decline
On 25 June, Divis Laboratories saw a notable 14.1% increase in open interest in its derivatives segment, rising from 65,002 to 74,164 contracts. This surge occurred despite the stock price declining 0.60% to ₹6,710.85, underperforming the Pharmaceuticals & Biotechnology sector’s 0.17% fall and the Sensex’s marginal 0.05% decline. Futures volume was robust at 48,585 contracts, with a combined futures and options value of approximately ₹12,620 crores, highlighting significant liquidity and market participation.
The divergence between rising open interest and falling price often signals new short positions or fresh long positions being established at lower levels. Given Divis Laboratories’ strong medium- to long-term technical positioning above key moving averages and its recent upgrade to a Buy rating, the latter scenario appears more plausible. Traders may be accumulating long exposure through derivatives, anticipating a potential rebound or sector recovery.
Want to dive deeper on Divis Laboratories Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Weekly Price Performance: Divis Laboratories vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-06-22 | Rs.6,784.95 | +0.65% | 36,342.26 | +0.46% |
| 2026-06-23 | Rs.6,743.15 | -0.62% | 35,959.97 | -1.05% |
| 2026-06-24 | Rs.6,751.05 | +0.12% | 36,151.68 | +0.53% |
| 2026-06-25 | Rs.6,710.85 | -0.60% | 36,133.32 | -0.05% |
Key Takeaways
Positive Signals: The upgrade to a Buy rating by MarketsMOJO on 22 June was supported by strong quarterly financials, improved technical indicators, and a net-debt-free balance sheet. The stock’s ability to remain above key moving averages and the surge in derivatives open interest suggest sustained medium-term bullish momentum. Institutional ownership at 39.51% further reinforces confidence in the company’s fundamentals.
Cautionary Notes: Despite the upgrade, the stock declined 0.45% over the week, underperforming the Sensex’s 0.11% fall. The premium valuation metrics, including a P/B ratio of 10.7 and PEG of 3.5, imply that much growth is already priced in, increasing vulnerability to earnings disappointments. The divergence between rising open interest and falling price on 25 June indicates mixed short-term sentiment, with some investors possibly establishing short positions or awaiting clearer catalysts.
Conclusion
Divis Laboratories Ltd’s week was characterised by a blend of optimism and caution. The MarketsMOJO upgrade to Buy, backed by robust financial results and bullish technical signals, provided a positive backdrop. However, the stock’s slight weekly decline and mixed price-derivatives dynamics reflect short-term uncertainty. Investors should monitor open interest trends and delivery volumes closely as leading indicators of market positioning. The company’s strong fundamentals and market leadership remain intact, but valuation premiums and moderate growth rates warrant careful observation in the coming weeks.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
